UK MDS Patient Support Group

LONDON - - More Than Half of Blood Cancer Experts (56 Percent) say Less Priority is Given to Rarer Cancers Compared to Other Common Cancers The results of a new survey, launched today by the UK MDS Patient Support Group, shows that almost a fifth (18 percent) of patients suffering from myelodysplastic syndromes (MDS) - a type of blood cancer - could have lived for longer if they had been able to access treatments that are currently not approved by NICE for treatment on the NHS.[1] Furthermore, the survey revealed that more than half (56 percent) of blood cancer experts surveyed believe that less priority is given to rarer cancers versus other common cancers.